Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
Outline of Final Research Achievements |
Idendified anti-enterovirus compounds were classified into direct-acting compounds to viral proteins, and PI4KB/OSBP inhibitors. PI4KB/OSBP pathway is required for formation of a virus replication complex by accumulating unesterified cholesterol on virus-induced membrane structure, rather than directly involved in viral RNA synthesis. These results suggested that evaluation of the effectiveness of the PI4KB/OSBP inhibitors is essential in development of anti-enterovirus drug targeting host factor activity.
|